Heat Biologics (HTBX) Issued Key Patent on Combination Platform Therapy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/29/2026

1. NOW
2. GOOGL
3. MSFT
4. FTNT
5. EBAY
6. TENB
7. BIIB
8. CMG
9. KLAC
10. ETSY

Go back to Heat Biologics (HTBX) Issued Key Patent on Combination Platform Therapy

Heat Biologics Issued Key Patent on Combination Platform Therapy

September 2, 2020 7:31 AM EDT

Superior pre-clinical activity compared to conventional costimulatory antibody combination administered systemically

DURHAM, NC / ACCESSWIRE / September 2, 2020 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announced it has been issued a patent (US Patent No. 10,758,611) by the U.S. Patent and Trademark Office (USPTO) covering compositions of matter that are part of Heat's gp96 platform in combination with a T cell costimulatory agonist in a single... More